IXHL — Incannex Healthcare Ltd ADR
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$3.29
+$0.11 (+3.46%)
Incannex Healthcare Ltd ADR (IXHL) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Joel Bradley Latham, based in 8 Century Circuit, Sydney, NSW, Australia, 2153, with about 12 employees. Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Net income was -$6.4M. IXHL currently screens at market cap $44.3M.
Use this IXHL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IXHL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IXHL SEC filings page. Lician reads the product cache first so this HTML stays unique to Incannex Healthcare Ltd ADR even when a live quote feed is slow.
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
IXHL Key Statistics
Market Cap
$44.27M
Volume
198,098
Previous Close
$3.62
Day Range
$3.61 – $3.92
P/B Ratio
0.58
EPS
-$1.35
Revenue
$0.00
Net Income
-$46.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
12
IXHL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0.00 | $12.00K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$46.88M | -$18.46M | -$48.81M |
| EPS (Diluted) | -$1.35 | -$1.15 | -$3.32 |
Total Assets
$20.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$15.04M
Operating Cash Flow
-$12.51M
Free Cash Flow
$0.00
Incannex Healthcare Ltd ADR Company Information
- President, CEO & Executive Director
- Joel Bradley Latham
- Headquarters
- 8 Century Circuit, Sydney, NSW, Australia, 2153
- Website
- www.incannex.com
- Phone
- 61 4 0984 0786
- IPO / Founded
- 2022-03-02
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic